Product Information
XCOPRI 200 MG TABLET is a brand product labeled by SK Life Science, Inc., priced at $39.8682 per EA under NDC 71699020030. Its NADAC has been published 279 times since Apr 21, 2021.
FDA first approved this application on Mar 10, 2020.
Strength
200 mg/1
Manufacturer
SK Life Science, Inc.NDC
71699020030
Classification
Brand
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
8/19/2026
Active Ingredients
CENOBAMATEApproval Type
New Drug (NDA)
FDA Application
NDA212839FDA Approved
3/10/2020
On Market Since
3/12/2020
Pharmacological Classes
Price Statistics
The NADAC for XCOPRI 200 MG TABLET has been published 279 times since Apr 21, 2021, and over the history we have for it it has risen 21.2%. The table below summarizes its recorded NADAC range and movement.
| Current price | $39.8682 per EA |
|---|---|
| All-time high | $39.9414 (May 13, 2026) |
| All-time low | $32.9067 (Apr 21, 2021) |
| 52-week high | $39.9414 |
| 52-week low | $38.7642 |
| Median price | $35.5886 |
| Average price | $36.4176 |
| Largest weekly change | +6.0% (Jan 3, 2024) |
| Weeks tracked | 279 |
| Tracking since | Apr 21, 2021 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the cenobamate market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of XCOPRI 200 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for XCOPRI 200 MG TABLET, manufactured by SK Life Science, Inc., is $39.8682 per EA (NDC 71699020030), effective Aug 19, 2026.
How has the price of XCOPRI 200 MG TABLET changed over time?
Over the history we have for it, the NADAC for XCOPRI 200 MG TABLET has risen 21.2%. It has been tracked across 279 weekly CMS publications since Apr 21, 2021.
What are the highest and lowest recorded NADAC prices for XCOPRI 200 MG TABLET?
Since Apr 21, 2021, the NADAC for XCOPRI 200 MG TABLET has ranged from a low of $32.9067 (Apr 21, 2021) to a high of $39.9414 (May 13, 2026), with a median of $35.5886 per EA.
Are there cheaper alternatives to XCOPRI 200 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of XCOPRI 200 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures XCOPRI 200 MG TABLET?
XCOPRI 200 MG TABLET (NDC 71699020030) is labeled by SK Life Science, Inc., and CMS classifies it as a brand product.